Kryptos Biotechnologies, a Hayward, CA-based Biotech company that uses light to generate heat and control temperature, raised $10M in Series A funding.
The round was led by Osang Healthcare.
The company intends to use the funds to advance the clinical study of the respiratory combo tests, which in turn will help receive FDA approval by 2025.
Led by CEO Jinyong Lee, Kryptos Biotechnologies is a life science startup providing technology, called photothermal heating, which uses light to generate heat and control temperature for various types of molecular diagnostic devices and life science instruments. Their diagnostics systems enable clinicians to make the right treatment decision in less time by providing a PCR-based point-of-care molecular diagnostic system that gives a sample-to-answer in 20 minutes while ensuring the same level of accuracy with lab systems.
Along with the financing, the company has entered into a strategic partnership with Osang Healthcare for the manufacturing and distribution of its product.
